(Reuters) -Swiss drugmaker Roche plans to accelerate the development of its anti-obesity drugs to challenge rivals like Eli ...

Two new studies published in the New England Journal of Medicine suggest that Zepbound, the latest and most potent injectable ...

Research shows the drug can cut the risk of serious cardiovascular issues like heart attack and stroke in certain patients.

GLP-1 medicines, mostly acylated peptides like semaglutide and liraglutide, have pleiotropic effects beyond weight and ...

It makes sense why Pfizer wants to compete in the market for weight loss therapies. There's more than one credible estimate ...

Healthcare company Roche said its trial-stage daily pill showed an average 6.1 percent weight loss in four weeks ...

An anti-obesity drug, the first such medicine to become available in Japan, has been approved for manufacturing and sales by an expert panel of the health ministry. The decision, made Nov. 28 ...

Recent health news covers Japan's Eisai company shares plummeting after the EU's rejection of their Alzheimer's drug, and Swiss drugmaker Roche accelerating its weight-loss drug development to compete ...

The program aims to help people lose weight and keep it off, even after they stop weight-loss meds, in order to prevent ...

Opinion: Our guest opinion writers argue that more can be done to help troops get their physical fitness squared away, both ...

Drugs such as semaglutide are synthetic versions of GLP-1, which stimulate insulin and can also help people feel full. One of ...

Roche is among a growing number of would-be rivals to Novo and Eli Lilly, whose weight-loss injections have been in feverish ...